Therapeutic Drug Monitoring of Levetiracetam in Different Trimesters of Pregnant Women with Epilepsy in a Tertiary Care Center: A Prospective Study
Neurology India · 2024
DOI: 10.4103/ni.ni_439_22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology India, 2024. Verfasst von J Kumaravel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants, Drug Monitoring, Epilepsy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Background
Levetiracetam is the most commonly used antiepileptic drug in pregnant women due to its low teratogenic risk profile, favorable pharmacokinetic characteristics, and safety profile. Serum levels of levetiracetam vary in epilepsy during pregnancy. Therefore, the aim of the study was to evaluate the serum levels of levetiracetam during different trimesters of pregnancy by using therapeutic drug monitoring (TDM). Materials and Methods: This was a single-center, prospective study. Pregnant women with epilepsy on levetiracetam were enrolled after getting written informed consent from them. Serum trough levels of levetiracetam were estimated at all trimesters by high-performance liquid chromatography (HPLC).
Results
The study included 16 participants with mean ± standard deviation (SD) age of 27.75 ± 4 years. There were nine (56.2%) participants with generalized seizure disorder and seven (43.8%) participants of focal seizure disorder. Among 16 patients, 10 (62.5%) participants were on levetiracetam alone and six (37.5%) participants were on levetiracetam combined with other antiepileptic drugs. In a total of 48 trough samples, 45 sample concentrations were below the therapeutic range of 12–46 mg/l and three sample concentrations were within the therapeutic range. There was a statistically significant difference in the concentration–dose ratio (CDR) of levetiracetam between the third and first trimesters ( P -value 0.018).
Conclusion
There was a statistically significant difference in serum levetiracetam concentration between the third and first trimesters. A well-conducted, intensive pharmacokinetic sampling study in PWWE with a control group is needed in future to evaluate the whole pharmacokinetic profile of levetiracetam and to correlate the clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Kumaravel, J., Sarma, P., Suri, V., Singh, P., Prakash, A., & Medhi, B. (2024). Therapeutic Drug Monitoring of Levetiracetam in Different Trimesters of Pregnant Women with Epilepsy in a Tertiary Care Center: A Prospective Study. Neurology India. https://doi.org/10.4103/ni.ni_439_22
Vancouver
Kumaravel J, Sarma P, Suri V, Singh P, Prakash A, Medhi B. Therapeutic Drug Monitoring of Levetiracetam in Different Trimesters of Pregnant Women with Epilepsy in a Tertiary Care Center: A Prospective Study. Neurology India. 2024. doi:10.4103/ni.ni_439_22
BibTeX
@article{Kumaravel2024,
author = {Kumaravel, J and Sarma, Phulen and Suri, Vanita and Singh, Parampreet and Prakash, Ajay and Medhi, Bikash},
title = {Therapeutic Drug Monitoring of Levetiracetam in Different Trimesters of Pregnant Women with Epilepsy in a Tertiary Care Center: A Prospective Study},
journal = {Neurology India},
year = {2024},
doi = {10.4103/ni.ni_439_22}
}
EUVIMED